Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis.

News | Cardiogenic Shock

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 22, 2022 — Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella ...

September 22, 2022

Results of the CLASP IID Trial Presented at TCT and published simultaneously in JACC: Cardiovascular Interventions

News | Structural Heart

Novel TEER Repair Device Meets Primary Endpoint in Treating Degenerative Mitral Regurgitation in Patients Not Eligible for Surgery

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter ...

September 20, 2022

Dr. Gagan Singh, Dr. Susheel Kodali, and Dr. Azeem Latib with principal investigator, Dr. Adrian Ebner, following the initial first-in-human cases with the Supira System.

News | Cardiogenic Shock

Supira Medical Announces Successful First-in-Human Use of its Next Generation Percutaneous Ventricular Assist Device

September 19, 2022 — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation ...

September 19, 2022

Results also demonstrate the benefits for patients of Abbott's TriClip™ for tricuspid regurgitation, Amulet™ for atrial fibrillation and Portico™ for aortic stenosis

News | Structural Heart

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

September 17, 2022 — Abbott today announced data from five late-breaking presentations showing the benefits of its ...

September 17, 2022

Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets

News | Structural Heart

First-ever Comparison of MicroCT and Histology in Self-expanding Transcatheter Aortic Valve Replacement Patients with Hypo-attenuated Leaflet Thickening

September 17, 2022 — Medtronic today announced findings from its Pathological Study of Hypo-Attenuated Leaflet ...

September 17, 2022

The Impella CP with SmartAssist heart pump is a minimally invasive, temporary heart pump that uses real-time intelligence associated with improved survival and heart recovery. (Graphic: Business Wire)

News | Hemodynamic Support Devices

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

September 17, 2022 — Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To ...

September 17, 2022

Results from largest randomized TAVR trial to date presented at TCT 2022

News | Embolic Protection Devices

Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL Cerebral Protection System

September 17, 2022 — Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

September 17, 2022

Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

News | TCT

Edwards Pascal Precision Transcatheter Valve Repair System Receives FDA Approval for Degenerative Mitral Regurgitation

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

September 16, 2022

Results from Largest Ever Real-World Evaluation of the MANTA Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve

News | Vascular Closure Devices

Co-Author of the Karolinska 1000 Consecutive MANTA Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

September 16, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced that Dr. Magnus ...

September 16, 2022

RECOVER IV is an on-label, two arm RCT that is designed to provide the clinical evidence needed to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock.

News | Cardiogenic Shock

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...

September 16, 2022

Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures

News | TCT

Philips Showcases Clinical Data and Solutions Designed to Deliver Better Cardiac Care with Greater Efficiency at TCT 2022

September 15, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its ...

September 15, 2022

Findings reveal AFib patients are fearful of complications from the condition, but not all are treating their AFib quicky after diagnosis

News | Atrial Fibrillation

Biosense Webster AFib Survey Findings Reveal Surprising Patient Behaviors and At-Risk Population Awareness Gaps

September 14, 2022 — In recognition of Atrial Fibrillation (AFib) Awareness Month, Biosense Webster, Inc., part of ...

September 14, 2022

Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference, Oct. 30-Nov. 3, 2022, have been announced.

News | Cardiovascular Education

Late-breaking Clinical Trial presentations announced for The VEINS and VIVA Conference

September 14, 2022 — Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INte ...

September 14, 2022

Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

News | Stroke

Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib

September 13, 2022 — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for ...

September 13, 2022

News | STEMI

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

September 13, 2022 — ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related ...

September 13, 2022